Related Experiment Videos
[Deferoxamine protects against gentamicin ototoxicity]
1Department of Otorhinolaryngology, XiJing Hospital, Fourth Military Medical University, Xi'an 710032.
Zhonghua Er Bi Yan Hou Ke Za Zhi
|May 27, 2003
Summary
Deferoxamine (DFO) significantly reduces gentamicin (GM) induced ototoxicity in guinea pigs by mitigating cochlear damage, suggesting DFO as a potential therapeutic agent against GM-induced hearing loss.
Area of Science:
- Ototoxicity research
- Pharmacology
- Nephrotoxicity studies
Context:
- Gentamicin (GM) is a widely used antibiotic with known ototoxic side effects.
- Developing strategies to prevent GM-induced hearing loss is crucial for patient safety.
- Deferoxamine (DFO) is an iron chelator with potential protective properties.
Purpose:
- To investigate the efficacy of deferoxamine (DFO) in preventing gentamicin (GM) induced ototoxicity in a guinea pig model.
- To explore the underlying mechanisms of DFO's protective effects against GM ototoxicity.
Summary:
- Guinea pigs were treated with GM alone, DFO alone, or a combination of GM and DFO. Hearing thresholds and cochlear morphology were assessed using acoustic brainstem response (ABR) and electron microscopy.
- Results showed that DFO significantly reduced hearing threshold shifts and preserved cochlear morphology in GM-treated animals.
- DFO did not affect GM serum levels but reduced markers of oxidative stress and iron concentration in cochlear tissue, suggesting a role for free radicals and iron in GM ototoxicity.
Impact:
- This study highlights the potential of deferoxamine (DFO) as a therapeutic agent to mitigate gentamicin (GM) ototoxicity.
- Findings suggest that free radicals and iron are involved in the mechanism of GM-induced hearing damage.
- The research provides a basis for further investigation into DFO's clinical application for preventing antibiotic-induced hearing loss.